2022³â Á¦35ȸ ´ëÇѺñ´¢±âÁ¾¾çÇÐȸ Á¤±âÇмú´ëȸ ¹× ÃÑȸ : 2022-08-27 |
|
2022³â Á¦35ȸ ´ëÇѺñ´¢±âÁ¾¾çÇÐȸ Á¤±âÇмú´ëȸ ¹× ÃÑȸ : 2022-08-27 ±³À°ÀÏÀÚ : 2022-08-27 ±³À°Àå¼Ò : ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ ±³À°ÁÖÁ¦ : 2022³â Á¦35ȸ ´ëÇѺñ´¢±âÁ¾¾çÇÐȸ Á¤±âÇмú´ëȸ ¹× ÃÑȸ ÁÖÃÖ±â°ü : ´ëÇѺñ´¢±âÁ¾¾çÇÐȸ ´ã´çÀÚ : ±èÀºÁÖ ¿¬¶ôó : 02-704-8574 À̸ÞÀÏ : app@app2010.com ±³À°Á¾·ù : ºñ´¢ÀÇÇаú Âü¼®¿¹»óÀοø : 150¸í Èñ¸ÁÆòÁ¡ : 4Á¡ Áö¿ª : ¼¿ïƯº°½Ã ±³À°½Ã°£ : 5 ½Ã°£ 30ºÐ ¼¼ºÎ¼ö°·á : 40,000¿ø ºñ°í ±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ ±âŸ 08-27 ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 08:30~09:00 Registration () ±âŸ 08-27 ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 09:00~09:05 President¡¯s Welcome () ±âŸ 08-27 ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 09:05~09:10 Congratulatory Remark () ±³À°½Ã°£ 08-27 ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 09:10~10:00 Podium Session I: Renal Cell Carcinoma Á¶Áø¼±(ÇѸ²ÀÇ´ë) ±³À°½Ã°£ 08-27 ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 10:00~10:20 The Reminiscence of Korean Urological Oncology Society ¾ÈÇÑÁ¾(¿ï»êÀÇ´ë) ÈÞ½Ä 08-27 ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 10:20~10:40 Break () ±³À°½Ã°£ 08-27 ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 10:40~10:57 The optimal management for incidentally detected localized prostate cancer after BPH surgery/Active treatment °¼º±¸(°í·ÁÀÇ´ë) ±³À°½Ã°£ 08-27 ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 10:57~11:14 The optimal management for incidentally detected localized prostate cancer after BPH surgery/Observation or active surveillance ¼Û¿Ï(¼º±Õ°üÀÇ´ë) ±³À°½Ã°£ 08-27 ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 11:14~11:32 The optimal management in patients with BCG-unresponsive NMIBC/Early radical cystectomy ±èÅÂȯ(°æºÏÀÇ´ë) ±³À°½Ã°£ 08-27 ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 11:32~11:50 The optimal management in patients with BCG-unresponsive NMIBC/Intravesical therapy or systemic immunotherapy ³²Á¾±æ(ºÎ»êÀÇ´ë) ±âŸ 08-27 ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 11:50~12:00 BLUE Çмú»ó ½Ã»ó () ±âŸ 08-27 ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 12:00~12:10 Project 2022 Proposal ¹× °ø¸ð³í¹® ½Ã»ó () ½Ä»ç 08-27 ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 12:10~13:20 Lunch () ±³À°½Ã°£ 08-27 ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 13:20~13:50 Understanding tumor immune microenvironment ¹Ú¿õ¾ç(¼º±Õ°üÀÇ´ë »ï¼ºÀ¯Àüü¿¬±¸¼Ò) ±³À°½Ã°£ 08-27 ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 13:50~14:40 Podium Session II: Urothelial Cancer À̵¿Çö(ÀÌÈÀÇ´ë) ÈÞ½Ä 08-27 ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 14:40~15:00 Break () ±³À°½Ã°£ 08-27 ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 15:00~15:20 PARP inhibitors in the treatment of urologic cancer ±ÇÈÖ¾È(ÇѾçÀÇ´ë) ±³À°½Ã°£ 08-27 ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 15:20~15:40 Updated risk calculator for urologic cancer ³ëÅÂÀÏ(°í·ÁÀÇ´ë) ±³À°½Ã°£ 08-27 ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 15:40~16:00 Perioperative systemic treatment in muscle invasive urothelial cancer ±èÇü¼®(µ¿±¹ÀÇ´ë) ±³À°½Ã°£ 08-27 ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 16:00~16:50 Podium Session III: Prostate Cancer Àü¼º¼ö(¼º±Õ°üÀÇ´ë) ±âŸ 08-27 ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 16:50~17:20 Çмú»ó ½Ã»ó ¹× ÃÑȸ () ±âŸ 08-27 ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 17:20~17:30 Æóȸ»ç () |
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù. |
|